首页> 外文OA文献 >Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature
【2h】

Utility of adjuvant whole abdominal radiation therapy in ovarian clear cell cancer (OCCC): a pragmatic cohort study of women with classic immuno-phenotypic signature

机译:佐剂全腹部放射治疗在卵巢透明细胞癌中的效用(OCCC):经典免疫表型签名妇女的务实队列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background To evaluate the initial experience and clinical utility of first-line adjuvant intensity-modulated whole abdominal radiation therapy (WART) in women with ovarian clear cell cancer (OCCC) referred to an academic center. Methods Progression-free and overall survival was analyzed in a pragmatic observational cohort study of histologically pure OCCC patients over-expressing HNF-1ß treated between 2013 and end-December 2018. An in-house intensity-modulated WART program was developed from a published pre-clinical model. Radiation dose-volume data was curated to American Association of Physics in Medicine (AAPM) Task Group 263 recommendations. A dedicated database prospectively recorded presenting characteristics and outcomes in a standardized fashion. Results Five women with FIGO (2018) stage IA to IIIA2 OCCC were treated with first-line WART. Median age was 58 years (range 47–68 years). At diagnosis CA-125 was elevated in 4 cases (median 56 kU/L: range 18.4–370 kU/L) before primary de-bulking surgery. Severe premorbid endometriosis was documented in 3 patients. At a median follow-up of 77 months (range 16–83 mo.), all patients remain alive and progression-free on clinical, biochemical (CA-125), and 18Fluoro-deoxyglucose (FDG) PET/CT re-evaluation. Late radiation toxicity was significant (G3) in 1 case who required a limited bowel resection and chronic nutritional support at 9 months post-WART; 2 further patients had asymptomatic (G2) osteoporotic fragility fractures of axial skeleton at 12 months post-radiation treated with anti-resorptive agents (denosumab). Conclusions The clinical utility of intensity-modulated WART in OCCC over-expressing HNF-1β was suggested in this small observational cohort study. The hypothesis that HNF-1β is a portent of platinum-resistance and an important predictive biomarker in OCCC needs further confirmation. Curating multi-institutional cohort studies utilizing WART by means of “Big Data” may improve OCCC care standards in the future.
机译:抽象背景为了评价女性卵巢透明细胞癌(OCCC)的初步经验和一线佐剂强度调制全腹放射治疗(疣)的临床效用称为学术中心。方法无进展生存率和总生存率在组织学纯OCCC患者务实的观察性队列研究,分析过表达HNF-1β2013年十二月底,2018年的内部调强疣程序是基于先前公开的开发与治疗临床前模型。辐射剂量批量数据策划到美国物理协会医学(AAPM)工作组263的建议。专用数据库前瞻性记录在一个标准化的方式呈现的特点和成果。结果五名妇女与FIGO(2018)阶段IA到IIIA2 OCCC用一线疣处理。平均年龄为58岁(47-68范围岁)。主去膨胀剂手术前:(范围18.4-370 KU / L值56 KU / L)在诊断CA-125 4例升高。严重的病前子宫内膜异位症3例记载。在中位随访77个月(16-83月),所有患者仍然存活和无进展的临床,生化(CA-125),和18Fluoro脱氧葡萄糖(FDG)PET / CT重新评估。晚期放射毒性是需要9个月的限制期肠切除慢性营养支持谁1例显著(G3)发布疣;图2进一步例有无症状中轴骨骼的(G2)骨质疏松脆性骨折在12个月与抗吸收剂(狄诺塞麦)进行后处理的辐射。结论调强疣OCCC过度表达HNF-1β的临床应用建议在这个狭小的观察性队列研究。该假说认为HNF-1β是铂电阻的征兆和OCCC一个重要的预测生物标志物还需要进一步确认。策划利用疣的“大数据”的手段多机构的队列研究可以提高在未来OCCC保健标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号